November 18, 2026
Health news, explained with evidence
LIVE
Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia

New Startup Marrow Therapeutics Launches with $173 Million to Tackle Sickle Cell Disease

🔬 Research 1 min read 👁 5

Biotech entrepreneur Romesh Subramanian has launched Marrow Therapeutics, securing $173 million in funding to develop a potential alternative to gene therapy for sickle cell disease.

New Startup Marrow Therapeutics Launches with $173 Million to Tackle Sickle Cell Disease🔬Research

Photo: statnews.com

Key points

  • Marrow Therapeutics launched with $173 million in Series A and B funding.
  • Backers include Scion Life Sciences, venBio, and OrbiMed.
  • The startup aims to develop a treatment as effective as gene therapy without its drawbacks.

A newly formed biotechnology enterprise, Marrow Therapeutics, has emerged with $173 million in combined Series A and B financing to pursue alternative treatments for sickle cell disease. The funding round was supported by prominent backers including Scion Life Sciences, venBio, and OrbiMed, according to an announcement made on Tuesday by founder and biotech entrepreneur Romesh Subramanian.

For years, investigators and financial backers have sought therapeutic approaches that match the efficacy of complex gene therapies while avoiding their significant procedural drawbacks. Subramanian expressed optimism regarding the new venture's approach, stating that the therapy is anticipated to offer comparable effectiveness for patients, though clinical proof remains to be established.

What to know: While the financial backing is substantial, the initiative is in its early stages, and clinical data confirming its efficacy in humans has not yet been detailed. Readers considering any medical treatments or clinical trials should consult a qualified physician for personalized guidance.

Source statnews.com — statnews.com/2026/11/17/new-startup-developing-novel-sickle-cell-an… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.